| Nov 19 |
Sana Biotechnology: The Story Becomes Murkier
|
| Nov 13 |
Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher
|
| Nov 11 |
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
|
| Nov 8 |
Sana Biotechnology Non-GAAP EPS of -$0.27
|
| Nov 8 |
Sana: Q3 Earnings Snapshot
|
| Nov 8 |
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
|
| Nov 5 |
Sana plunges 19% after discontinuing programs
|
| Nov 5 |
Sana lowered to market perform by JMP over data uncertainty
|
| Nov 5 |
Sana to lay off staff, deepen autoimmune focus in latest retrenchment
|
| Nov 4 |
Sana drops two programs to focus on diabetes, autoimmune diseases
|
